Chiron Corporation serves human suffering with over 50 different products for perceiving, preventing and treating ailments the world over through its global Blood Testing, Vaccines and biopharmaceutical businesses.

Pulminiq is the formulated solution prepared by using USP grade Cyclosporine as its key ingredient for the inhalation, containing 300mg / 4.8 ml of Cyclosporine. Pulminiq is designed to deliver Cyclosporine directly into the lungs by attaining higher drug absorption at the site of rejection as compared with intravenous or oral medications prepared using Cyclosporine. Cyclosporine is the approved therapy with immuno suppressant used in the treatment of kidney related ailments as well as liver and allogeneic heart transplant recipients.

The United States – Food and Drugs Administrative Authorities have already approved Pulminiq inhaled formulation in solution form of Cyclosporine for the typical treatment of heart, kidney and liver transplant patients since over 20 years now. For the Pulminiq NDA, Chiron Corporation is on the lookout for an indication to improve endurance and avert rejection in the patients intended to receiving allogeneic lung transplants, associated with the regular immuno suppressive therapies.

According to the clinical data furnished with the particular NDA exhibited the 79 percent reduction in the risk of death [P=.007] as well as the 72 percent reduction in the risk for chronic rejection or death [P=.001] for the patients receiving Pulminiq as compared to the patients that received placebo. On final clearance by the U.S. FDA, Pulminiq would be the first ever drug formulation which would be indicated exclusively for the treatment of lung transplant patients.